{"denoms":[{"counts":[{"groupId":"BG000","value":"13"}],"units":"Participants"}],"groups":[{"description":"Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion or withdrew consent then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 for four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.","id":"BG000","title":"Ruxolitinib Then Ruxolitinib + Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.36","value":"74.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"description":"Stage I: Relatively few cancer cells have spread throughout the body. Levels of red blood cells and calcium in the blood are normal. No bone tumors. M-protein in the blood or urine is very low. Possibly no symptoms of disease.\n\nStage II: A moderate number of cancer cells have spread throughout the body.\n\nStage III: A large number of cancer cells have spread throughout the body. There may be 1 or more of the following:\n\n* Decreased red blood cells, causing anemia\n* High amounts of calcium in the blood\n* More than 3 bone tumors (plasmacytomas)\n* High levels of M-protein in blood or urine","paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Unknown"}],"paramType":"NUMBER","title":"Stage of multiple myeloma at initial diagnosis","unitOfMeasure":"participants"}]}